{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"OG000","title":"ALK-positive Solid Tumors"}],"populationDescription":"DOR was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause and could not be calculated due to an insufficient number of participants with the event.","reportingStatus":"POSTED","timeFrame":"From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 5 years)","title":"Duration of Response (DOR) as Determined by Both the Investigator and by BICR Per RECIST v1.1","type":"SECONDARY"}